{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-005188","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.783570+00:00","generated_at":"2026-06-07T01:30:30.722418+00:00","sec_items":["1.01","3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atara raises $15M via pre-funded warrants; Nasdaq warns of bid price deficiency","bullets":["Gross proceeds of ~$15M from sale of pre-funded warrants to purchase up to 27,272,727 shares at $0.55/warrant.","Warrants exercisable immediately at $0.0001/share, no expiration; proceeds for working capital and R&D.","Nasdaq notified ATRA that bid price closed below $1.00 for 30 consecutive days; 180-day cure period until July 8, 2024.","If not cured, company may transfer to Nasdaq Capital Market or effect reverse stock split; delisting possible.","Offering expected to close January 10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-005188","json":"https://secwatch.observer/filing/0001193125-24-005188.json","markdown":"https://secwatch.observer/filing/0001193125-24-005188.md","text":"https://secwatch.observer/filing/0001193125-24-005188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524005188/0001193125-24-005188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524005188/d703135d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:30:30.722418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdbebb6f0fb9260588170badd2193fda7b341f1d","claim":"Atara Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"January 8, 2024, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Common Stock closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided a period of 180","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524005188/0001193125-24-005188-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"e9d0530736d264ec26cd3f7e145cc36883cc3774","claim":"Atara Biotherapeutics, Inc. entered into Purchase Agreement with certain purchasers valued at approximately $15.0 million (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024, Atara Biotherapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Registered Offering”) pre-funded warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524005188/0001193125-24-005188-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"approximately $15.0 million"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}